Market closed
BeyondSpring/$BYSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeyondSpring
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
Ticker
$BYSI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
40
Website
BeyondSpring Metrics
BasicAdvanced
$53M
-
-$0.28
0.31
-
Price and volume
Market cap
$53M
Beta
0.31
52-week high
$3.63
52-week low
$0.98
Average daily volume
21K
Financial strength
Current ratio
2.596
Quick ratio
0.265
Long term debt to equity
-2.149
Total debt to equity
-4.123
Management effectiveness
Return on assets (TTM)
-18.51%
Return on equity (TTM)
46.97%
Valuation
Price to book
-1.61
Price to tangible book (TTM)
-1.61
Price to free cash flow (TTM)
-3.123
Growth
Earnings per share change (TTM)
-48.08%
3-year earnings per share growth (CAGR)
-44.58%
What the Analysts think about BeyondSpring
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BeyondSpring stock.
BeyondSpring Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BeyondSpring Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BeyondSpring News
AllArticlesVideos
BeyondSpring Files 2024 Annual Report on Form 10-K
GlobeNewsWire·3 weeks ago
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
GlobeNewsWire·3 months ago
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BeyondSpring stock?
BeyondSpring (BYSI) has a market cap of $53M as of April 20, 2025.
What is the P/E ratio for BeyondSpring stock?
The price to earnings (P/E) ratio for BeyondSpring (BYSI) stock is 0 as of April 20, 2025.
Does BeyondSpring stock pay dividends?
No, BeyondSpring (BYSI) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next BeyondSpring dividend payment date?
BeyondSpring (BYSI) stock does not pay dividends to its shareholders.
What is the beta indicator for BeyondSpring?
BeyondSpring (BYSI) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.